Back

All cause mortality in people with type 2 diabetes using SGLT-2 inhibitors compared to DPP4 inhibitors using the danish registries

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Real-world evidence on the cardiovascular effects of therapies for diabetes Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Puriya Daniel Wuertz Yazdanfard

Nordsjaellands Hospital, Hilleroed (Denmark)

8 More presentations in this session

Presentation thumbnail
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
Mr B. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
The effect of metformin use on the risk of atrial fibrillation in patients with type 2 diabetes: data from the UK biobank
Doctor T. Guo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after one year of observation.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video
Presentation thumbnail
Empaglifozin modifies the arterial stiffness in type-2 diabetic patients: a preliminary report.
Doctor M. Feola (Mondovi, IT)
Abstract Slides Video
Presentation thumbnail
Identification and optimisation of a risk stratified cohort of patients with type 2 diabetes through the delivery of a enhanced pharmacist-led service
Mr S. Mcbrien (Belfast, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Real-world evidence on the cardiovascular effects of therapies for diabetes

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
thumbnail
Congress Session
Late-Breaking Clinical Science: cardiometabolic medicine
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources